These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Zolmitriptan stimulates a Ca(2+)-dependent K(+) current in C6 glioma cells stably expressing recombinant human 5-HT(1B) receptors. Le Grand B; Panissié A; Perez M; Pauwels PJ; John GW Eur J Pharmacol; 2000 Jun; 397(2-3):297-302. PubMed ID: 10844127 [TBL] [Abstract][Full Text] [Related]
6. Lack of an effect of zolmitriptan (Zomig, 311C90) on psychometric task performance: results of a placebo-controlled study in healthy volunteers. Mercer AJ; Lamb RJ; Rolan PE; Gibbens M; Posner J Psychopharmacology (Berl); 1998 Dec; 140(4):398-404. PubMed ID: 9888613 [TBL] [Abstract][Full Text] [Related]
7. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Martin GR Cephalalgia; 1997 Oct; 17 Suppl 18():4-14. PubMed ID: 9399012 [TBL] [Abstract][Full Text] [Related]
8. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). Peck RW; Seaber EJ; Dixon R; Gillotin CG; Weatherley BC; Layton G; Posner J Br J Clin Pharmacol; 1997 Dec; 44(6):595-9. PubMed ID: 9431839 [TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers. Dixon R; Gillotin C; Gibbens M; Posner J; Peck RW Br J Clin Pharmacol; 1997 Mar; 43(3):273-81. PubMed ID: 9088582 [TBL] [Abstract][Full Text] [Related]
10. Central sites of actions of zolmitriptan and sumatriptan: 5HT1B, 5HT1D and 5HT1F receptor distribution. Pascual J; Castro ME; Pazos A Cephalalgia; 1997 Oct; 17(6):711. PubMed ID: 9350394 [No Abstract] [Full Text] [Related]
11. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). Martin GR; Robertson AD; MacLennan SJ; Prentice DJ; Barrett VJ; Buckingham J; Honey AC; Giles H; Moncada S Br J Pharmacol; 1997 May; 121(2):157-64. PubMed ID: 9154322 [TBL] [Abstract][Full Text] [Related]
12. Effects of zolmitriptan (Zomig) on central serotonergic neurotransmission as assessed by active oddball auditory event-related potentials in volunteers without migraine. Hughes AM; Dixon R; Dane A; Kemp J; Cummings L; Yates RA Cephalalgia; 1999 Mar; 19(2):100-6; discussion 73. PubMed ID: 10214535 [TBL] [Abstract][Full Text] [Related]
13. Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers. Smith DA; Cleary EW; Watkins S; Huffman CS; Polvino WJ Int J Clin Pharmacol Ther; 1998 Jun; 36(6):301-5. PubMed ID: 9660035 [TBL] [Abstract][Full Text] [Related]
14. Zolmitriptan: a review of its use in migraine. Spencer CM; Gunasekara NS; Hills C Drugs; 1999 Aug; 58(2):347-74. PubMed ID: 10473025 [TBL] [Abstract][Full Text] [Related]
17. Zolmitriptan reverses blink reflex changes induced during the migraine attack in humans. de Tommaso M; Guido M; Libro G; Sciruicchio V; Puca F Neurosci Lett; 2000 Jul; 289(1):57-60. PubMed ID: 10899408 [TBL] [Abstract][Full Text] [Related]
18. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig). Proietti-Cecchini A; Afra J; Schoenen J Cephalalgia; 1997 Dec; 17(8):849-54; discussion 799. PubMed ID: 9453273 [TBL] [Abstract][Full Text] [Related]
19. Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Goadsby PJ; Knight YE Cephalalgia; 1997 May; 17(3):153-8. PubMed ID: 9170337 [TBL] [Abstract][Full Text] [Related]
20. Comparison of more and less lipophilic serotonin (5HT1B/1D) agonists in a model of trigeminovascular nociception in cat. Hoskin KL; Goadsby PJ Exp Neurol; 1998 Mar; 150(1):45-51. PubMed ID: 9514827 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]